{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:42:22Z","timestamp":1778892142347,"version":"3.51.4"},"reference-count":116,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2018,1,2]]},"DOI":"10.1080\/14737140.2018.1412259","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T11:54:45Z","timestamp":1512129285000},"page":"3-18","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Emerging data on improving response to hormone therapy: the role of novel targeted agents"],"prefix":"10.1080","volume":"18","author":[{"given":"Neelima","family":"Vidula","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.05.008"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.09.011"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-2332"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2823"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-0652"},{"issue":"19","key":"CIT0006","first-page":"7025","volume":"61","author":"Yang X","year":"2001","journal-title":"Cancer Res"},{"issue":"10","key":"CIT0007","first-page":"2552","volume":"54","author":"Ottaviano YL","year":"1994","journal-title":"Cancer Res"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0060-1"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-CT101"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"issue":"507","key":"CIT0011","volume":"34","author":"Finn R","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30109-2"},{"key":"CIT0014","unstructured":"Ribociclib FDA (Kisqali). Cited 51517. 2017; March 14. Available online: https:\/\/wwwfdagov\/drugs\/informationondrugs\/approveddrugs\/ucm546438htm"},{"key":"CIT0015","unstructured":"NCT02102490. A study of abemaciclib (LY2835219) in participants with previously treated breast cancer that has spread (MONARCH1). [cited 2016 Mar 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02102490?term=ABEMACICLIB&rank=16"},{"issue":"1000","key":"CIT0016","volume":"35","author":"Sledge G","year":"2017","journal-title":"J Clin Oncol"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.7251"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0190"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0807-8"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu390"},{"key":"CIT0021","volume-title":"Proceedings of the 2016 San Antonio Breast Cancer Symposium; AACR; Cancer Re","volume":"77","author":"Mayer I","year":"2017"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS15-S5-07"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS15-S1-04"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.34.4879"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.25"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3618"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-0035"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0195"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1172\/jci41680"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3282-x"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-2402"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0143"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2833"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.3331"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.10.003"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.8391"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.0708"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"CIT0040","unstructured":"Andre F. UNIRAD. Randomised, double blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease after receiving at least 1 year of adjuvant hormone therapy. [cited 2016 Jan 30]. Available online at http:\/\/www.icr.ac.uk\/our-research\/our-research-centres\/clinical-trials-and-statistics-unit\/clinical-trials\/unirad"},{"key":"CIT0041","unstructured":"SWOG 1207. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy \u00b1 one year of everolimus in patients with high-risk, hormone receptor-positive and HER2\/Neu negative breast cancer. e3 breast cancer study - evaluating everolimus with endocrine therapy. ClinicalTrials.gov Registry Number: NCT01674140. [cited 2016 Jan 30]. Available online at http:\/\/swog.org\/Visitors\/ViewProtocolDetails.asp?ProtocolID=2248"},{"key":"CIT0042","unstructured":"Neoadj ph 2 AI plus everolimus in postmenopausal women w\/ER Pos\/HER2 neg, low risk score. ClinicalTrials.gov Identifier:NCT02236572. [cited 2016 Jun26]. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02236572"},{"key":"CIT0043","unstructured":"NCT01698918. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER1, HER2- metastatic or locally advanced breast cancer (Bolero-4). [cited 2016 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01698918"},{"key":"CIT0044","unstructured":"NCT01783444. A phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer. (BOLERO-6). [cited 2016 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01783444"},{"key":"CIT0045","unstructured":"NCT00570921. Study of combined fulvestrant and everolimus in advanced\/metastatic breast cancer after aromatase inhibitor failure. (BRE-43). [cited March 26, 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00570921"},{"key":"CIT0046","unstructured":"NCT02344550. Study of GnRH plus leterozole +\/2 everolimus for premenopausal women with metastatic breast cancer (LEO). [cited 2016 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02344550"},{"key":"CIT0047","unstructured":"NCT02404051. Fulvestrant and EVerolimus Plus EXemestane in metastatic breast cancer (FEVEX). [cited 2016 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02404051"},{"key":"CIT0048","unstructured":"NCT02123823. A phase Ib\/II randomized study of BI 836845 in combination with exemestane and everolimus versus exemestane and everolimus alone in women with locally advanced or metastatic breast cancer. [cited 2016 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02123823?term5BI1836845&rank53"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.0518"},{"key":"CIT0050","volume-title":"Cancer Res; Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium","author":"Baselga J","year":"2015"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30376-5"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu329.1"},{"issue":"4","key":"CIT0053","volume":"77","author":"Di Leo A","year":"2017","journal-title":"AACR; Cancer Res"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Krop I, Johnston S, Mayer I, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer \u2013 Part I results San Antonio Breast Cancer Symposium Abstract S2-02 2014.","DOI":"10.1158\/1538-7445.SABCS14-S2-02"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00106-6"},{"key":"CIT0056","unstructured":"NCT02437318. Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment. (SOLAR-1). [cited 2016 Jun 26]. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437318"},{"key":"CIT0057","unstructured":"NCT02340221. SANDPIPER study: a study of taselisib + fulvestrant versus placebo + fulvestrant in patients with advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy. [cited 2016 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02340221"},{"issue":"520","key":"CIT0058","volume":"34","author":"Dickler M","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0059","volume-title":"Molecular biology of the cell","author":"Alberts B","year":"2002","edition":"4"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-1551"},{"issue":"11","key":"CIT0061","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"Fry DW","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.628985"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1530\/erc-10-0262"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.16.10882"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008867200"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-14-0387"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-06-0613"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.020"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.177"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-0509"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2258"},{"key":"CIT0074","unstructured":"FDA. Palbociclib. [cited Feb 12 2015]. Available online. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm432886.htm"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"CIT0077","unstructured":"Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive\/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). [cited 2014 May 16] National Institutes of Health Clinical Trials. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02028507."},{"key":"CIT0078","unstructured":"PD 0332991 and anastrozole for stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http:\/\/wwwcancergov\/clinicaltrials\/search\/view?cdrid=742660&version=HealthProfessional&protocolsearchid=12773356"},{"key":"CIT0079","unstructured":"A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). National Institutes of Health Clinical Trials. [cited 2014 May 16]. Available at: http:\/\/clinicaltrialsgov\/show\/NCT01864746"},{"key":"CIT0080","unstructured":"Palbociclib + endocrine therapy for HR+ BrCa National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http:\/\/wwwcancergov\/clinicaltrials\/search\/view?cdrid=757030&version=HealthProfessional&protocolsearchid=12773356"},{"key":"CIT0081","doi-asserted-by":"crossref","unstructured":"Mayer E, Gropper A, Tung N, et al. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: a phase II feasibility study. ASCO Chicago, IL Abstract TPS654. 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.tps654"},{"key":"CIT0082","unstructured":"NCT02513394. PALbociclib collaborative adjuvant study: a randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)\/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS). [cited Jul 10 2017]. Available online: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02513394?show_locs=Y#locn"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-A276"},{"key":"CIT0084","unstructured":"Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer: (MONALEESA-2). National Institutes of Health Clinical Trials. Accessed 2014 May 27. Available at: http:\/\/clinicaltrials.gov\/show\/NCT01958021"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"CIT0086","unstructured":"FDA. Kisqali (ribociclib) prescribing information. cited 5 15 17. 2017. Available online: https:\/\/wwwaccessdatafda\/gov\/drugsatfda_docs\/label2017\/209092s000lblpdf"},{"key":"CIT0087","unstructured":"NCT02422615. Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer. (MONALEESA-3). [cited 2017 Jul 16]. Available online: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02422615"},{"key":"CIT0088","unstructured":"NCT02278120. Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). [cited Jul. 16.2017]. Available online: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02278120"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.168"},{"key":"CIT0090","doi-asserted-by":"crossref","unstructured":"Bardia A, Modi S, Chavez-Mac Gregor M, et al. Phase Ib\/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+\/HER2- metastatic breast cancer. ASCO Chicago, IL Abstract 535. 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.535"},{"key":"CIT0091","unstructured":"Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http:\/\/www.cancer.gov\/clinicaltrials\/search\/view?cdrid=750319&version=HealthProfessional&protocolsearchid=12773476"},{"key":"CIT0092","unstructured":"Study of LEE011 with fulvestrant and BYL719 or BKM120 in advanced breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http:\/\/www.cancer.gov\/clinicaltrials\/search\/view?cdrid=759365&version=HealthProfessional&protocolsearchid=12773476"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-CT232"},{"key":"CIT0094","doi-asserted-by":"crossref","unstructured":"Patnaik A, Rosen LS, Tolaney SM et al. LY2835219, a novel cell cycle inhibitor selective for CDK 4\/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. ASCO Chicago, IL Abstract 534. 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.534"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0754"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7585"},{"key":"CIT0097","unstructured":"Broderck J Abemaciclib improves PFS in phase III Monarch 3 breast cancer trial. OncLive. 2017; April. [cited 2017 Jul 20]. Available online: http:\/\/www.onclive.com\/web-exclusives\/abemaciclib-improves-pfs-in-phase-iii-monarch-3-breast-cancer-trial"},{"key":"CIT0098","volume-title":"European Society for Medical Oncology 2017 meeting","author":"Di Leo A","year":"2017"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.6155"},{"key":"CIT0100","unstructured":"Hurvitz SM, Fernandez A, Al E. Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer 2016 San Antonio Breast Cancer Symposium Abstract S4-06. 2016."},{"key":"CIT0101","volume-title":"Proceedings of the 2016 San Antonio Breast Cancer Symposium; AACR; Cancer Res","volume":"77","author":"Rugo H","year":"2017"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-2458"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0533-z"},{"key":"CIT0104","doi-asserted-by":"crossref","unstructured":"Connolly R, Zhao F, Miller K, et al. E2112: a randomized phase III trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer. 2014. San Antonio Breast Cancer Symposium. Abstract OT2-1-06.","DOI":"10.1158\/1538-7445.SABCS14-OT2-1-06"},{"key":"CIT0105","unstructured":"Dovitinib plus an aromatase inhibitor for metastatic breast cancer. ClinicalTrials.gov Identifier: NCT01484041. [cited 2016 Jan 31]. Available online at: https:\/\/clinicaltrials.gov\/show\/NCT01484041"},{"key":"CIT0106","unstructured":"NCT02053636. A phase II trial testing oral administration of lucitanib in patients with fibroblast growth factor receptor (FGFR)1-amplified or non-amplified estrogen receptor positive metastatic breast cancer (FINESSE). [cited 2016 Jun 27]. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02053636"},{"key":"CIT0107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.506"},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465"},{"key":"CIT0109","unstructured":"NCT01823835. A study of GDC-0810 single agent or in combination with palbociclib and\/or a luteinizing hormone-releasing hormone (LHRH) agonist in women with locally advanced or metastatic estrogen receptor positive breast cancer. Accessed online: ClinicalTrials gov 111017"},{"key":"CIT0110","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3599"},{"key":"CIT0111","unstructured":"NCT02007512. Efficacy and safety study of enzalutamide in combination with exemestane in patients with advanced breast cancer. Available online: ClinicalTrialsgov Accessed 111017."},{"key":"CIT0112","volume-title":"San Antonio Breast Cancer Symposium","author":"Yardley DAKI","year":"2017"},{"key":"CIT0113","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.66.1595"},{"key":"CIT0114","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.2388"},{"key":"CIT0115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-13-1014"},{"key":"CIT0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.04.003"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2018.1412259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T19:55:57Z","timestamp":1660074957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2018.1412259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,2]]}},"alternative-id":["10.1080\/14737140.2018.1412259"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2018.1412259","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}